HealthKodiak Sciences Shares Surge 178% After Eye Drug Trial Success
Kodiak Sciences Inc. shares jumped over 178% after positive Phase 3 trial results for two experimental treatments targeting wet age-related macular degeneration. The stock rose from $32.35 to a high of $90.88 on September 28. Both drugs met key efficacy goals, performing comparably to existing treatments but with less frequent injections, potentially improving patient convenience.
NDTV Business·3h ago


